Cite
HARVARD Citation
Tucker, D. et al. (2021). The 5‐year follow‐up of a real‐world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. British journal of haematology. pp. 1035-1038. [Online].